Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
- PMID: 30316012
- PMCID: PMC6348045
- DOI: 10.1016/j.jtho.2018.10.001
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
Abstract
Introduction: Malignant pleural mesothelioma is a disease primarily associated with exposure to the carcinogen asbestos. Whereas other carcinogen-related tumors are associated with a high tumor mutation burden, mesothelioma is not. We sought to resolve this discrepancy.
Methods: We used mate-pair (n = 22), RNA (n = 28), and T cell receptor sequencing along with in silico predictions and immunologic assays to understand how structural variants of chromosomes affect the transcriptome.
Results: We observed that inter- or intrachromosomal rearrangements were present in every specimen and were frequently in a pattern of chromoanagenesis such as chromoplexy or chromothripsis. Transcription of rearrangement-related junctions was predicted to result in many potential neoantigens, some of which were proven to bind patient-specific major histocompatibility complex molecules and to expand intratumoral T cell clones. T cells responsive to these predicted neoantigens were also present in a patient's circulating T cell repertoire. Analysis of genomic array data from the mesothelioma cohort in The Cancer Genome Atlas suggested that multiple chromothriptic-like events negatively impact survival.
Conclusions: Our findings represent the discovery of potential neoantigen expression driven by structural chromosomal rearrangements. These results may have implications for the development of novel immunotherapeutic strategies and the selection of patients to receive immunotherapies.
Keywords: Chromoplexy; Chromosomal rearrangements; Chromothripsis; Mesothelioma; Neoantigens.
Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest Statement: The authors have no conflicts of interest relevant to this work to declare.
Figures




Comment in
-
Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?J Thorac Oncol. 2019 Feb;14(2):157-159. doi: 10.1016/j.jtho.2018.11.006. Epub 2018 Dec 28. J Thorac Oncol. 2019. PMID: 30598368 Free PMC article. No abstract available.
References
-
- Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591–1603. - PubMed
-
- Popescu NC, Chahinian AP, DiPaolo JA. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res 1988;48:142–147. - PubMed
-
- Taguchi T, Jhanwar SC, Siegfried JM, et al. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer research 1993. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical